Evaluation of Hepatitis B core related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Introduction
Better understanding of hepatitis B virus (HBV) biomarkers is needed. We evaluated Hepatitis B core related antigen (HBcrAg), in the United Kingdom (UK) and South Africa (SA).
Methods
We undertook a cross-sectional retrospective observational study of adults with chronic HBV infection from the UK (n=142) and SA (n=211). We recorded clinical and laboratory parameters and quantified HBcrAg. We report HBcrAg distribution, relationship with other biomarkers, and performance in risk stratification based on point of care test (POCT) thresholds.
Results
SA and UK cohorts were similar in sex and age (p>0.05), but significantly different in ethnicity, HIV coinfection, HBeAg-positivity and proportion with HBV viral load (VL) >200,000 IU/ml (all p<0.001). More of the untreated SA population had HBcrAg >5.3 log 10 U/ml compared to the UK (33% vs 9% respectively, p<0.0001). HBcrAg ≥4.3 log 10 U/ml (corresponding to a positive POCT) was 100% sensitive and 92% specific for predicting VL >200,000 IU/ml in the UK, but not SA. HBcrAg positively correlated with alanine transferase (ALT) (p<0.001 in UK, p<0.01 in SA), and fibrosis/cirrhosis by APRI score (p = 0.03 in UK and p=0.008 in SA), but not by elastography or FIB-4 scores.
Discussion
HBcrAg distribution and relationship with other biomarkers differs between settings. HBcrAg (including POCT) may be a useful proxy for VL, but less so as a marker of disease progression, Its use needs tailoring to represent diverse populations.
